Skip Navigation

Coronavirus (COVID-19) information for Dana-Farber patients & families Learn more

CAR T-Cell Therapy for Multiple Myeloma

  • CAR T-cell therapy is a promising treatment for patients with multiple myeloma, whose disease has relapsed or is not responding to (refractory) prior treatments. It is a highly-specialized therapy that involves genetically modifying a patient's own T cells to attack their multiple myeloma using a target called B-cell maturation antigen (BCMA). The FDA has approved Abecma (idecabtagene vicleucel), the first CAR T-cell therapy for multiple myeloma. Dana-Farber/Brigham and Women's Cancer Center (DF/BWCC) is a leader in bringing new CAR T-cell therapies to patients in need and led the clinical trial that led to FDA approval of Abecma.

    Abecma is approved for multiple myeloma that has relapsed after or is refractory to at least four prior treatments. The clinical trial of Abecma showed the CAR T-cell therapy to be highly effective for patients whose disease had relapsed after or not responded to multiple prior treatments.

    Patients are evaluated carefully to determine if this therapy is appropriate for them. As a new product, there may be limited availability of Abecma. Your physician will discuss this with you and whether a clinical trial of another CAR T-cell product may be an option. Learn more about CAR T-cell therapy.

    DF/BWCC also offers clinical trials of other CAR T-cell therapies for multiple myeloma.

  • Grandmother Living Active Life after CAR-T Treatment
    The FDA recently approved the first CAR T-cell therapy for multiple myeloma. Nikhil Munshi, MD, and clinical trial participant, Susan Voigt share what this significant advance means for patients.